Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

Group 1 - The company, Boji Pharmaceutical, is actively expanding its overseas clinical business by establishing subsidiaries abroad and forming an international business department [2] - The company is recruiting talent with international business experience to support its global expansion efforts [2]

Group 1 - The management of Boji Pharmaceutical expresses confidence in the company's long-term development and has never relaxed its efforts in operations and growth [1] - The company is focused on enhancing its profitability and is committed to returning value to investors through continuous dividends [1] - Boji Pharmaceutical aims to create long-term value for its investors [1]

证券日报网讯 1月16日，博济医药在互动平台回答投资者提问时表示，公司持续关注行业前沿领域的技 术发展，并做好相应的技术储备。 （文章来源：证券日报） ...

Group 1 - The AI healthcare and AI pharmaceutical sectors experienced significant fluctuations, with notable declines in stock prices [1] - Hongbo Pharmaceutical saw a drop of over 18%, while Nossger fell nearly 15% [1] - Other companies such as International Medicine, Boji Pharmaceutical, Jiahe Meikang, and Berry Genomics also reported declines exceeding 5% [1]

Group 1 - The CRO index experienced a decline of 2.66% during intraday trading, with all constituent stocks showing a downward trend [1] - Hongbo Pharmaceutical led the decline with a drop of 19%, followed by Nossig at 9.65%, Yinos at 15%, Chengdu XianDao at 5%, and Boji Pharmaceutical at 4% [1]

据博济医药消息，日前，博济医药携旗下子公司BlOTrialMed（美国博创）与欧洲临床研究组织 （CRO）Pharmaxi正式宣布达成战略合作。此次三方协作将深度整合博济医药的全流程研发能力、 BlOTrialMed的北美临床服务优势与Pharmaxi的欧洲本地化资源，为中国生物医药企业提供"中美欧"跨 区域临床试验一站式解决方案。 ...

证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交2.85亿元，其中，买入成交额为2.26亿 元，卖出成交额为5937.18万元，合计净买入1.66亿元。 具体来看，今日上榜的营业部中，共有2家机构专用席位现身，即卖一、卖三，合计买入金额2403.47万 元，卖出金额2755.00万元，合计净卖出351.53万元。 博济医药今日涨停，全天换手率22.34%，成交额7.76亿元，振幅17.35%。龙虎榜数据显示，机构净卖出 351.53万元，营业部席位合计净买入1.70亿元。 深交所公开信息显示，当日该股因日收盘价涨幅达20.00%上榜，机构专用席位净卖出351.53万元。 博济医药1月13日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 开源证券股份有限公司西安西大街证券营业部 | 7323.18 | 0.36 | | 买二 | 国投证券股份有限公司深圳深南大道华侨城大厦证券营 业部 | 4450.81 | 0.00 | | 买三 | 东方证券股份有限公司扬州文汇东路 ...

证券之星消息，1月13日医疗服务板块较上一交易日上涨4.15%，诺思格领涨。当日上证指数报收于 4138.76，下跌0.64%。深证成指报收于14169.4，下跌1.37%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301333 | 诺思格 | 76.48 | 20.01% | 5.52万 | | 3.97亿 | | 301257 | 電影斯 | 72.24 | 20.00% | 2.29万 | | 1.56亿 | | 301230 | 泓博医药 | 56.64 | 20.00% | 5.72万 | | 3.24亿 | | 301060 | 兰卫医学 | 13.28 | 19.96% | 1 35.21万 | | 4.41亿 | | 300404 | 博济医药 | 12.92 | 19.96% | 62.71万 | | 7.76亿 | | 300244 | 迪安诊断 | 29.16 | 11.90% | 151.60万 | | 46.46亿 | ...

Market Overview - A-shares experienced a collective pullback on January 13, with the Shanghai Composite Index ending a 17-day winning streak, closing down 0.64% [1] - The total trading volume in the Shanghai and Shenzhen markets reached a historical high of 3.7 trillion [1] Sector Performance - Significant declines were observed in various sectors, including commercial aerospace, satellite internet, and military industries, with many stocks dropping over 8% [3] - The large aircraft and military sectors also faced downturns, with several stocks hitting the daily limit down [3] - The commercial aerospace index fell by 6.15%, with a net outflow of 230.78 billion [4] Individual Stock Movements - Over 1,600 stocks rose, with more than 70 stocks hitting the daily limit up, while the commercial aerospace sector saw over 60 stocks limit down or drop more than 10% [3] - Specific stocks such as Aerospace Electronics and Beidou Star Communication experienced significant declines, with many stocks in the sector down by nearly 10% [7] Investment Insights - Analysts suggest that the current market sentiment may indicate a nearing peak, with potential for further structural upward trends despite short-term volatility [12] - Key investment strategies include avoiding speculative risks in popular sectors, focusing on policy-driven industries, and maintaining diversified portfolios to balance risk and return [14] - The emphasis is on sectors with strong earnings growth and valuation alignment, particularly in technology manufacturing and innovative healthcare [14]